Dexamethasone

Chemical formula: C₂₂H₂₉FO₅  Molecular mass: 392.461 g/mol  PubChem compound: 5743

Therapeutic indications

Dexamethasone is indicated for:

Endocrine exophthalmos

Population group: only adults (18 years old or older)

Thyroid eye disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Multiple myeloma

Population group: only adults (18 - 65 years old)

Dexamethasone is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Multiple myeloma

Population group: only elderly (65 years old or older)

Dexamethasone is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Marginal keratitis

Population group: only adults (18 years old or older)

Marginal keratitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Corneal stromal edema

Population group: only adults (18 years old or older)

Corneal stromal oedema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anterior uveitis

Population group: only adults (18 years old or older)

Anterior uveitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Episcleritis

Population group: only adults (18 years old or older)

Episcleritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Scleritis

Population group: only adults (18 years old or older)

Scleritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute atopic conjunctivitis

Population group: only adults (18 years old or older)

Acute atopic conjunctivitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anaphylaxis

Population group: only adults (18 years old or older)

Anaphylaxis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polymyalgia rheumatica

Population group: only adults (18 years old or older)

Polymyalgia rheumatica

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polyarteritis nodosa

Population group: only adults (18 years old or older)

Polyarteritis nodosa

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Primary adrenocortical insufficiency

Population group: only adults (18 years old or older)

Primary adrenocortical insufficiency

Secondary adrenocortical insufficiency

Population group: only adults (18 years old or older)

Secondary hypocortisolism

Crohn's disease

Population group: only adults (18 years old or older)

Crohn's disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ulcerative colitis

Population group: only adults (18 years old or older)

Colitis gravis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Raised intracranial pressure secondary to cerebral tumours and infantile spasms

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Raised intracranial pressure and additionally at least one of
Neoplasm of brain
† Infantile spasm

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cerebral edema

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Cerebral edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bronchial asthma

Population group: only adults (18 years old or older)

Airway hyperreactivity

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Aspiration pneumonitis

Population group: only adults (18 years old or older)

Aspiration pneumonitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Toxic epidermal necrolysis

Population group: only adults (18 years old or older)

Toxic epidermal necrolysis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Carpal tunnel syndrome

Population group: only adults (18 years old or older)

Carpal tunnel syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Tenosynovitis

Population group: only adults (18 years old or older)

Tenosynovitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Rheumatoid arthritis

Population group: only adults (18 years old or older)

Rheumatoid arthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Osteoarthritis

Population group: only adults (18 years old or older)

Osteoarthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cystic acne

Population group: only adults (18 years old or older)

Cystic acne

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lichen simplex

Population group: only adults (18 years old or older)

Lichen simplex chronicus

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Keloid scar

Population group: only adults (18 years old or older)

Cheloid of skin

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Shock

Population group: only adults (18 years old or older)

Shock

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Diabetic macular edema (DME)

Population group: only adults (18 years old or older)

Diabetic macular edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Branch retinal vein occlusion with macular edema (BRVO)

Population group: only adults (18 years old or older)

Branch retinal vein occlusion with macular edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Central retinal vein occlusion with macular edema

Population group: only adults (18 years old or older)

Central retinal vein occlusion with macular edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-infectious uveitis

Population group: only adults (18 years old or older)

Inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Coronavirus disease 2019 (COVID-19) which require supplemental oxygen therapy

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Dexamethasone is indicated in the treatment of coronavirus disease 2019 (COVID-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require supplemental oxygen therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Dexamethasone is contraindicated in the following cases:

Viral disease

Viral disease

Psychotic disorder

Psychotic disorder

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: NEOFORDEX Tablet
Summary of Product Characteristics (SPC) 2018: OZURDEX Intravitreal implant in applicator
Summary of Product Characteristics (SPC) 2017: DROPODEX Eye drops, solution
Summary of Product Characteristics (SPC) 2018: DEXAMETHASONE Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈